Histogen: Down as FDA puts on hold tissue defect treatment study

Histogen

20/01/2021 11:12

** Regenerative medicine maker's shares  HSTO.O  fall ~15%
to $1.00 premarket
    ** Co on Tuesday after market said U.S. FDA has put on
clinical hold its application to start human trials of
experimental implant, HST-003, for treatment of cartilage
defects in knee  urn:newsml:reuters.com:*:nGNX4J3qJ2
    ** Agency in its verbal communication with HSTO cites
pending information regarding treatment's chemistry,
manufacturing and controls as reason for clinical hold
    ** Co says it is yet to receive written notice of clinical
hold from FDA, which the agency expects to provide by Feb. 12
    ** HST-003 is anti-inflammatory that can stimulate the
growth of stem cells in damaged areas to induce tissue
regeneration - HSTO
    ** Up to Tuesday's close, stock had risen 55.6% this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))